These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Enfuvirtide (Fuzeon): the first fusion inhibitor. Williams IG Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892 [TBL] [Abstract][Full Text] [Related]
29. [Fusion inhibitors. One year therapy with T-20--initial evaluation]. Goebel FD MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046 [No Abstract] [Full Text] [Related]
30. Fusion inhibitor trials halted. AIDS Patient Care STDS; 2004 Mar; 18(3):182-3. PubMed ID: 15112641 [No Abstract] [Full Text] [Related]
31. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477 [TBL] [Abstract][Full Text] [Related]
32. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV. Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955 [No Abstract] [Full Text] [Related]
33. Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management. Murphy RL AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S12-8. PubMed ID: 19960652 [TBL] [Abstract][Full Text] [Related]
34. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Cervia JS; Smith MA Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775 [TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series. Polizzotto MN; Street AM; Wright E Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184 [TBL] [Abstract][Full Text] [Related]
36. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Harris M; Larsen G; Montaner JS AIDS; 2008 Jun; 22(10):1224-6. PubMed ID: 18525270 [TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673 [TBL] [Abstract][Full Text] [Related]
38. Drug profile: enfuvirtide (Fuzeon, ENF, T-20). Pham PA Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104 [No Abstract] [Full Text] [Related]
39. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors. TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653 [No Abstract] [Full Text] [Related]
40. Enfuvirtide: a new class of antiretroviral therapy for HIV infection. Leao JC; Frezzini C; Porter S Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]